Pharmacogenomics - How Genetics Can Guide Medication Choices

Two patients receive the same antidepressant at the same dose. One responds well after three weeks. The other has no response after two months and experiences persistent side effects. Their doctors eventually try a different drug, which works fine. The difference was never mysterious - it was biological. Their livers process that medication completely differently. A genetic test could have predicted that before the first prescription.

This is pharmacogenomics. It's not speculative. It has FDA-approved clinical guidelines, it influences prescribing in major health systems, and it's increasingly available at the consumer level. Here's what it actually tells you.

The genes that govern drug metabolism

Most drug metabolism in the body happens in the liver, and a family of enzymes called cytochrome P450s does the heavy lifting. These enzymes break down drugs into active or inactive forms, and their activity levels vary significantly from person to person based on genetic variants.

CYP2D6 is one of the most studied. It metabolizes roughly 25% of all prescribed drugs, including many antidepressants (SSRIs, tricyclics), antipsychotics, opioids, and beta-blockers. Variants in CYP2D6 divide people into four rough categories: poor metabolizers, intermediate metabolizers, normal metabolizers, and ultrarapid metabolizers.

A poor metabolizer given a standard dose of codeine, for example, converts very little of it to morphine, resulting in minimal pain relief. An ultrarapid metabolizer converts so much codeine to morphine so quickly that a standard dose can produce dangerous respiratory depression. Same drug, same dose, radically different outcomes - all predictable from a genetic test.

CYP2C19 governs metabolism of clopidogrel (a blood thinner), proton pump inhibitors, and some antidepressants. SLCO1B1 affects statin transport into liver cells; variants significantly increase the risk of statin-related muscle damage (myopathy). DPYD variants predict severe toxicity to a class of chemotherapy drugs. These are not edge cases. They have clinical consequences across large populations.

What "normal metabolizer" and "poor metabolizer" actually mean

These categories describe enzyme activity, not whether you're "good" or "bad" at processing medications. A poor metabolizer of a prodrug (one that requires conversion to become active) may get less benefit. A poor metabolizer of a drug where the drug itself is the active form may actually get more benefit, or more side effects, from the same dose because the compound builds up in their system.

Context matters for every gene-drug pair. The GeneLens pharmacogenomics report provides drug-specific interpretation, not just a global label. For CYP2D6 poor metabolizer status, the report tells you which specific drugs are affected and in what direction - whether that means adjusting dose, choosing an alternative medication, or simply being aware of a higher monitoring need.

Which medications have the strongest evidence

The Clinical Pharmacogenetics Implementation Consortium (CPIC) maintains evidence-based guidelines for gene-drug pairs. Their highest-confidence recommendations cover:

• Antidepressants: citalopram, escitalopram, sertraline, fluoxetine, paroxetine, amitriptyline, nortriptyline
• Antipsychotics: haloperidol, risperidone
• Pain medications: codeine, tramadol, oxycodone
• Cardiovascular: clopidogrel, simvastatin, warfarin
• Oncology: capecitabine, fluorouracil, mercaptopurine, thiopurines

If you take any of these medications or are likely to, pharmacogenomic testing has direct clinical relevance. The evidence tier matters: GeneLens only includes gene-drug pairs with CPIC Level A or B evidence, meaning the findings are strong enough to warrant clinical consideration.

How to actually use this information

The GeneLens pharmacogenomics report is designed to be shown to a prescribing clinician, not acted on alone. If you're a CYP2D6 poor metabolizer, you don't stop your current medications based on the report. You bring it to your doctor and have a conversation about whether your current regimen is optimal given what the genetics suggest.

For most people, the most useful application is prospective. When you're starting a new medication that falls in a high-evidence gene-drug category, your genetic profile is relevant input. Many health systems now have pharmacogenomics consult services. Some electronic health record systems even flag gene-drug interactions automatically when a patient's PGx profile is on file.

The framing that resonates most with patients: pharmacogenomics doesn't tell you what medication to take. It tells your doctor what your metabolism looks like, so they're not prescribing blind. For conditions where the first-choice medication doesn't work a quarter of the time - major depression is a good example - that's not a minor refinement. It can mean the difference between months of unnecessary suffering and a faster path to something that actually helps.